A more comprehensive dataset on JANX007 sends the group’s stock down.
ApexOnco Front Page
Recent articles
The agency approved eight oncology products over the month.
The Titan CD8-guiding technology seems to have spawned a new variant.
A single-arm trial was enough for J&J’s Inlexzo nod.
The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.
A Chinese phase 3 of the biparatopic DLL3 T-cell engager alveltamig will start soon.
The Kandlelit-007 trial will assess MK-1084 plus SC Keytruda across PD-L1 expression levels.
ESMO and the Triple Meeting approach.
